Minovia Therapeutics wins $350,000 grant for mitochondrial biomarkers – Longevity.Technology
Minovia Therapeutics Ltd., a clinical-stage biotechnology firm based in Haifa, Israel, has been awarded a $350,000 grant from the Countdown
Portfolia backs Gameto in launch of women’s health fund IV – Longevity.Technology
Portfolia has launched Women’s Health Fund IV, described as its most focused strategy in women’s health innovation, according to the
Omada Health study shows virtual PT yields significant cost savings – Longevity.Technology
Omada Health released research demonstrating that patients using its virtual physical therapy (PT) program, Omada for Joint & Muscle Health,
The seven shifts needed to accelerate longevity science
McKinsey Health Institute report calls for change to facilitate the development of biomedical interventions targeting the aging process. A new
Oldies-But-Goodies, August 2025 Edition – Peter Attia
This week, I’m sharing another collection of oldies-but-goodies—pieces from our newsletter archive that address a variety of topics of continued
The missing ingredient in the longevity revolution
Doyle Lokitiyakul, Communications Lead of Public Longevity Group, says trust is key to turning longevity science into real societal impact.
Minovia lands funding to develop mitochondria biomarkers
Countdown for a Cure provides grant to advance development of blood-based biomarkers for mitochondrial health. Israeli biotech Minovia Therapeutics has
ProHealth Longevity launches pharmaceutical-grade methylene blue supplement – Longevity.Technology
ProHealth Longevity has introduced a pharmaceutical-grade methylene blue dietary supplement aimed at enhancing mitochondrial function, cellular energy, and cognitive performance,
Immortal Dragons backs Frontier Bio in advancing 3D biofabrication – Longevity.Technology
Immortal Dragons, a US$40 million purpose-driven longevity fund based in Singapore, has announced a strategic investment in Frontier Bio, a
Alnylam to advance zilebesiran into global phase 3 hypertension study – Longevity.Technology
Alnylam and its partner Roche will initiate a global Phase 3 cardiovascular outcomes trial for zilebesiran by the end of
Banner year for Mesoblast with FDA approval and launch of Ryoncil – Longevity.Technology
Mesoblast Limited on August 28, 2025, reported a landmark performance: its first U.S. Food and Drug Administration approval and successful
Telomir Pharmaceuticals sees new in vitro evidence supporting Telomir-1 epigenetic potential – Longevity.Technology
Telomir Pharmaceuticals, a preclinical-stage biotechnology firm, today released new in vitro findings highlighting its lead candidate, Telomir-1. According to the